<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04007614</url>
  </required_header>
  <id_info>
    <org_study_id>APHP190093</org_study_id>
    <secondary_id>IDRCB : 2019-A00340-57</secondary_id>
    <nct_id>NCT04007614</nct_id>
  </id_info>
  <brief_title>Bone Health in Adolescents and Young Adults With Oral Macro-progestin Treatment</brief_title>
  <acronym>MACROS</acronym>
  <official_title>Bone Health in Adolescents and Young Adults With Oral Macro-progestin Treatment : Observational Study</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Assistance Publique - Hôpitaux de Paris</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Assistance Publique - Hôpitaux de Paris</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
  </oversight_info>
  <brief_summary>
    <textblock>
      Many factors are known to influence the acquisition of bone capital, especially estrogens in
      women. Estrogens have a major role in bone growth and the acquisition of bone mass peaks
      during puberty. This peak of bone mass is an important determinant of the risk of
      osteoporotic fracture in adulthood.

      It is known that estrogen deficiency increases the rate of bone remodeling and engenders an
      imbalance between resorption and bone formation, which can lead to osteoporosis.

      Oral estroprogestin contraceptives have an anti-gonadotropic effect and suppress estrogen
      secretion by the ovaries.

      However, studies in adolescents and young adults are rare and evidence of an effect on bone
      is still inconclusive, although there is increasing evidence that oral estroprogestin
      contraceptives in teenage girls may compromise the performance of the bone mass.

      Macro progestins treatments are prescribed in France to patients with contraindications to
      estroprogestin treatments. This practice is french and few recommendations exist on the use
      of these molecules by the oral route. There are no studies that describe the impact of these
      oral treatments on the bone health of young women treated.

      The Department of endocrinology, gynecology and pediatric diabetes of Necker-Enfants Malades
      hospital, follows many young girls taking a macro progestin treatment. This study is
      exclusively descriptive and will focus on the clinical and medical datas available on the
      bone health of these patients.
    </textblock>
  </brief_summary>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">April 2020</start_date>
  <completion_date type="Anticipated">February 2021</completion_date>
  <primary_completion_date type="Anticipated">February 2021</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Cohort</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Bone densitometry</measure>
    <time_frame>Day 0</time_frame>
    <description>Z score values compared to the reference values</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calcemia</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Ionized calcium</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Phosphor</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Magnesium</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Albumin</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Parathormone</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>25 OH vitamin D3</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinine</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Osteocalcin</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Bone alkaline phosphatase isoenzymes</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>C-terminal telopeptide of type I collagen</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Calciuria</measure>
    <time_frame>Day 0</time_frame>
    <description>Urine test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Natriuresis</measure>
    <time_frame>Day 0</time_frame>
    <description>Urine test</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Creatinuria</measure>
    <time_frame>Day 0</time_frame>
    <description>Urine test</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Clinical tolerance of treatment</measure>
    <time_frame>Day 0</time_frame>
    <description>6 questions asked to the patient under treatment, a yes or no answer is expected : presence of menstruating, regularity of cycles, out-of-periods bleeding, weight gain, acne, satisfaction in relation to treatment.</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Follicle stimulating hormone</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test, patients under macro progestin treatment at day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Gonadotrophin b LH</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test, patients under macro progestin treatment at day 0</description>
  </secondary_outcome>
  <secondary_outcome>
    <measure>Estradiol</measure>
    <time_frame>Day 0</time_frame>
    <description>Blood test, patients under macro progestin treatment at day 0</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Anticipated">50</enrollment>
  <condition>Contraception</condition>
  <condition>Macro-progestins</condition>
  <arm_group>
    <arm_group_label>Patients</arm_group_label>
    <description>Patients who have taken a macro progestin treatment for more than 6 months between 16 and 25 years of age.</description>
  </arm_group>
  <intervention>
    <intervention_type>Other</intervention_type>
    <intervention_name>Questionnaire</intervention_name>
    <description>Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment</description>
    <arm_group_label>Patients</arm_group_label>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients followed by the department of endocrinology, gynecology and pediatric diabetes of
        Necker hospital.
      </textblock>
    </study_pop>
    <sampling_method>Non-Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Patients aged 16 to 25 years old

          -  Patients followed at Necker-Enfants Malades hospital

          -  Patients who have taken or taking macro-progestins treatment by oral route (Luteran,
             Lutenyl, Surgestone) for at least 6 months between the age of 16 and 25 years

        Exclusion Criteria:

          -  Patients with a pathology or treatment that can alter bone mineral density
      </textblock>
    </criteria>
    <gender>Female</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Macroprogestins treatment.</gender_description>
    <minimum_age>16 Years</minimum_age>
    <maximum_age>25 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Sabrina Da Costa, MD</last_name>
    <role>Study Director</role>
    <affiliation>Hôpital Necker-Enfants Malades</affiliation>
  </overall_official>
  <overall_contact>
    <last_name>Maud Bidet, MD</last_name>
    <phone>1 71 19 64 38</phone>
    <email>maud.bidet@aphp.fr</email>
  </overall_contact>
  <overall_contact_backup>
    <last_name>Hélène Morel</last_name>
    <phone>1 71 19 63 46</phone>
    <phone_ext>+33</phone_ext>
    <email>helene.morel@aphp.fr</email>
  </overall_contact_backup>
  <location>
    <facility>
      <name>Hôpital Necker-Enfants Malades</name>
      <address>
        <city>Paris</city>
        <zip>75015</zip>
        <country>France</country>
      </address>
    </facility>
    <contact>
      <last_name>Maud Bidet, MD</last_name>
      <phone>1 71 19 64 38</phone>
      <phone_ext>+33</phone_ext>
      <email>maud.bidet@aphp.fr</email>
    </contact>
    <contact_backup>
      <last_name>Hélène Morel</last_name>
      <phone>1 71 19 63 46</phone>
      <phone_ext>+33</phone_ext>
      <email>helene.morel@aphp.fr</email>
    </contact_backup>
  </location>
  <location_countries>
    <country>France</country>
  </location_countries>
  <verification_date>March 2020</verification_date>
  <study_first_submitted>April 17, 2019</study_first_submitted>
  <study_first_submitted_qc>July 2, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 5, 2019</study_first_posted>
  <last_update_submitted>March 30, 2020</last_update_submitted>
  <last_update_submitted_qc>March 30, 2020</last_update_submitted_qc>
  <last_update_posted type="Actual">March 31, 2020</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor</responsible_party_type>
  </responsible_party>
  <keyword>Macro-progestins</keyword>
  <keyword>Bone health</keyword>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

